

Drug Formulary Update, October 2012

Updates to the HealthPartners Drug Formularies are listed below.

Updates for the Commercial Drug Formularies and the Minnesota Health Care Programs (Medicaid and Minnesota Care “State Programs”) Drug Formulary are listed first, and then changes for the Medicare Drug Formulary.

Commercial and Minnesota Health Care Programs

These changes are effective October 1, 2012, and apply to PreferredRx, GenericsPlusRx, and HealthPartners Minnesota Health Care Programs (Medicaid and Minnesota Care “State Programs”) Drug Formularies.

The formulary status is listed for the PreferredRx Drug Formulary. Variations in the formulary status are noted with an asterisk, with details in the notes section.

Medication	Status	Notes
Ciclesonide nasal (Zetonna)	NF	Preferred alternatives are available for this nasal steroid for allergies.
Cosopt (dorzolamide/timolol) PF	F*	* Cosopt PF has been added to the PreferredRx Formulary, and is non-formulary for GenericsPlusRx and for State Programs. Cosopt PF is a preservative-free eye drop. It is more costly than generic alternatives, and may have advantages for patients with sensitivities.
Dymista (azelastine/fluticasone) nasal	NF	Preferred alternatives are available for this combination nasal spray for allergies, including fluticasone (generic Flonase) and azelastine (generic Astelin).
Edarbyclor (Edarbi/chlorthalidone)	NF	Edarbyclor is a combination of the azilsartan (an angiotensin receptor blocker) with chlorthalidone. Preferred alternatives are available for this blood pressure medication, including losartan (generic Cozaar) and losartan/ HCTZ (generic Hyzaar).
Ezogabine (Potiga)	PA	Ezogabine is reserved <i>for prescribing by Neurology, for FDA-approved indications</i> . Ezogabine is a new seizure medication.
Lansoprazole kit (First-Lansoprazole)	Age	First-Lansoprazole is covered for members <= age 9. First-Lansoprazole is a compounding kit used to make a lansoprazole suspension.
Nitroglycerin ointment (Rectiv)	NF	Rectiv is a rectal ointment for pain associated with chronic anal fissure.
Omeprazole kit (First-Omeprazole)	Age	First- Omeprazole is covered for members <= age 9. First-Omeprazole is a compounding kit used to make an omeprazole suspension.

Medication	Status	Notes
Orlistat (Xenical and Alli)	PA*	<p>* Orlistat is prior authorization for the PreferredRx and GenericsPlusRx, and is excluded for State Programs.</p> <p>Prior authorization criteria for this weight loss medication have been updated, and apply to both the prescription form (Xenical) and the OTC form (Alli). Orlistat is available for:</p> <ol style="list-style-type: none"> 1. Obese patients (BMI > 30kg/m² or BMI > 27 with risk factors), enrolled and participating in a weight loss program addressing diet and exercise. Initial approvals are for three months. 2. Continued coverage after this 3-month trial is available for patients with a positive response (weight loss greater than 2 kg). Coverage for patients with a positive response will be extended for one year. 3. Extended coverage is available for patients continuing to respond (weight loss greater than 5% from baseline), with no limiting adverse reactions, and continuing participation in a weight loss program addressing diet and exercise.
Pylera (bismuth/ metronidazole/ tetracycline)	NF	Pylera is a combination of antibiotics for Helicobacter pylori infection.
Rifaximin (Xifaxan)	PA	<p>Prior authorization criteria have been updated. Rifaximin is available for:</p> <ol style="list-style-type: none"> 1. for hepatic encephalopathy: as a supplement to lactulose when side effects limit the dose of lactulose; or 2. for small bowel bacterial overgrowth: for patients with a positive diagnosis, who have tried and failed one course of appropriate antibiotic therapy. Approvals will be given for up to 10 days of therapy. Prolonged coverage is approved for up to 10 days per month for patients with a good response but with recurrent symptoms.
Rivaroxaban (Xarelto)	PA	<p>Rivaroxaban is available for patients with:</p> <ol style="list-style-type: none"> 1. Patients with a diagnosis of nonvalvular atrial fibrillation, or 2. Prophylaxis of deep vein thrombosis in patients undergoing knee or hip replacement surgery. <p>Dabigatran (Pradaxa) remains on formulary with prior authorization, for patients with a diagnosis of nonvalvular atrial fibrillation.</p>
Tafluprost (Zioptan) ophthalmic	F	<p>Tafluprost is a preservative-free eye drop for glaucoma. It is more costly than generic alternatives such as latanoprost (Xalatan), and may have advantages for patients with sensitivities.</p> <p>Lumigan and Travatan Z remain on formulary.</p>
Tdap (tetanus/ diphtheria/ pertussis) vaccine		Coverage has been expanded to allow pharmacists to administer Tdap. Pharmacies are now able to administer Tdap, bill HealthPartners through the pharmacy system, and charge patients using their preventative benefit (usually no co-pay).
Zoster vaccine (Zostavax)		Coverage has been expanded to allow pharmacists to administer Zostavax. Pharmacies are now able to administer Zostavax, bill HealthPartners through the pharmacy system, and charge patients using their preventative benefit (usually no co-pay).

Medicare Drug Formulary

These changes are effective October 1, 2012.

Medication	Status	Notes
Carfilzomib (Kyprolis)	T4 PA	Carfilzomib is available for: For new start patients: initial criteria - diagnosis of an FDA-approved indication, not otherwise excluded from Part D. Renewal criteria - documentation that disease progression on Kyprolis has not occurred. Three months, with approval every three months if renewal criteria are met. Carfilzomib was added to the Medicare Drug Formulary August 3 2012. A medical policy (for in-clinic administration) becomes effective on November 1. Carfilzomib requires prior authorization.
Ciclesonide nasal (Zetonna)	NF	Preferred alternatives are available for this nasal steroid for allergies.
Cosopt (dorzolamide/timolol) PF	T3	Preferred alternatives are available for this nasal steroid for allergies. Cosopt PF is a preservative-free eye drop. It is more costly than generic alternatives, and may have advantages for patients with sensitivities.
Dymista (azelastine/fluticasone) nasal	NF	Preferred alternatives are available for this combination nasal spray for allergies, including fluticasone (generic Flonase) and azelastine (generic Astelin).
Edarbyclor (Edarbi/chlorthalidone)	NF	Edarbyclor is a combination of the azilsartan (an angiotensin receptor blocker) with chlorthalidone. Preferred alternatives are available for this blood pressure medication, including losartan (generic Cozaar) and losartan/ HCTZ (generic Hyzaar).
Ezogabine (Potiga)	T4	Ezogabine is a new seizure medication.
Nitroglycerin ointment (Rectiv)	NF	Rectiv is a rectal ointment for pain associated with chronic anal fissure.
Pertuzumab (Perjeta)	T4 PA	Pertuzumab is available for: For new start patients: initial criteria - diagnosis of an FDA-approved indication, not otherwise excluded from Part D. Renewal criteria - documentation that disease progression has not occurred. Six months, with approval every six months if renewal criteria are met. Pertuzumab was added to the Medicare Drug Formulary June 29 2012. A medical policy (for in-clinic administration) becomes effective on November 1. Pertuzumab requires prior authorization.
Pylera (bismuth/metronidazole/tetracycline)	NF	Pylera is a combination of antibiotics for Helicobacter pylori infection.

Drug Formulary Update, p. 4 of 4

Medication	Status	Notes
Rivaroxaban (Xarelto)	T2 PA	Xarelto is available for patients with: 1. Patients with a diagnosis of nonvalvular atrial fibrillation, or 2. Prophylaxis of deep vein thrombosis in patients undergoing knee or hip replacement surgery. Dabigatran (Pradaxa) remains on formulary with prior authorization, for patients with a diagnosis of nonvalvular atrial fibrillation.
Tafluprost (Zioptan) ophthalmic	T2 PA	Reserved for patients with sensitivities to preservatives in other formulary products such as latanoprost, Lumigan, Travatan Z.

For Medicare: T1, covered generic T2, covered Brand T3, covered Brand T4, specialty

Formulary Information and Requests

Formulary Information is available at [HealthPartners.com/ Provider/ Pharmacy Services](http://HealthPartners.com/Provider/Pharmacy%20Services), including the [Drug Formularies](#).

Pharmacy Customer Service is available to providers (physicians and pharmacies) from 8AM - 6PM CST, Monday through Friday. After hours calls are answered by our Pharmacy Benefit Manager.

- Fax - 952-853-8700 or 1-888-883-5434. Telephone - 952-883-5813 or 1-800-492-7259.
- Mail - HealthPartners Pharmacy Services, 8170 33rd Avenue S, PO Box 1309, Mpls, MN 55440.